Prophylaxis reduces bacteremia in some kids

Print Friendly, PDF & Email


Agar plate showing
staphyloccus infection
Photo by Bill Branson
In a phase 3 study, levofloxacin prophylaxis significantly reduced bacteremia in children with acute leukemias who received intensive chemotherapy. However, the risk of bacteremia was not significantly reduced with levofloxacin in another cohort of children who underwent hematopoietic stem cell transplant (HSCT). Sarah Alexander,... [Read Article]
Print Friendly, PDF & Email

Neurotoxicity risk is higher for Hispanic kids with ALL

Print Friendly, PDF & Email


Syringe containing methotrexate
©Raimond Spekking
In a prospective study, Hispanic pediatric patients with acute lymphoblastic leukemia (ALL) had a risk of methotrexate-induced neurotoxicity that was more than twice the risk observed in non-Hispanic white patients. However, there was no significant difference in methotrexate neurotoxicity between non-Hispanic black patients and non-Hispanic white patients. In addition,... [Read Article]
Print Friendly, PDF & Email

New guidelines on antimicrobial prophylaxis

Print Friendly, PDF & Email


Cancer patient
receiving treatment
Photo by Rhoda Baer
Experts have published updated guidelines on antimicrobial prophylaxis for adults with cancer-related immunosuppression. The guidelines include antibacterial, antifungal, and antiviral prophylaxis recommendations, along with additional precautions, such as hand hygiene, that may reduce infection risk. The guidelines were developed by the American Society of Clinical Oncology (ASCO)... [Read Article]
Print Friendly, PDF & Email

Ibrutinib maintains efficacy over time

Print Friendly, PDF & Email


Micrograph showing CLL
Extended follow-up of the RESONATE-2 trial showed that first-line ibrutinib sustained efficacy in elderly patients with chronic lymphocytic leukemia (CLL). Patients who received ibrutinib had a long-term progression-free survival benefit over those who received chlorambucil. The depth of response to ibrutinib improved over time, which meant there was a substantial increase in... [Read Article]
Print Friendly, PDF & Email

Escalating MTX appears superior for T-ALL

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Escalating methotrexate (MTX) may produce better outcomes than high-dose MTX in children and young adults with T-cell acute lymphoblastic leukemia (T-ALL), according to research published in the Journal of Clinical Oncology. Researchers compared escalating and high-dose MTX given with the augmented Berlin-Frankfurt-Munster regimen in patients with T-ALL. Disease-free... [Read Article]
Print Friendly, PDF & Email

Fracture risk tied to death in women with MM

Print Friendly, PDF & Email


Femoral fracture
© Nevit Dilmen
Preexisting osteoporosis is an important risk factor for mortality in postmenopausal women who develop multiple myeloma (MM), according to researchers. They found that high fracture risk was associated with an increased risk of death in postmenopausal females with MM, independent of other clinical risk factors. Ashley E. Rosko, MD, of... [Read Article]
Print Friendly, PDF & Email

Predicting early outcomes in DLBCL

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
Measurement of circulating tumor DNA (ctDNA) could be a new and useful tool for predicting survival outcomes and response to therapy in patients with diffuse large B-cell lymphoma (DLBCL), according to researchers. Pretreatment ctDNA levels predicted 24-month event-free survival as well as overall survival in a prospective study. Changes... [Read Article]
Print Friendly, PDF & Email

Signal strength tied to potency of CAR T-cell therapy

Print Friendly, PDF & Email


Researcher in the lab
Photo by Daniel Sone
Investigators found that chimeric antigen receptor (CAR) T cells with stronger signaling capabilities were less effective against lymphoma cells in a mouse model. Intracellular signaling strength was a key determinant of T-cell fate in the study, which was published in Science Signaling. By contrast, CAR signaling pathways... [Read Article]
Print Friendly, PDF & Email

T-cell therapy induced CMRs with no CRS

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
A novel CD19-targeted T-cell therapy induced complete metabolic responses (CMRs) and no cytokine release syndrome (CRS) in patients with B-cell lymphomas in a first-in-human clinical study. All subjects achieving CMR at the 1-month safety and efficacy assessment continued to show CMR at 3 months, investigators reported at... [Read Article]
Print Friendly, PDF & Email

Gene signature might identify patients at risk of CAR T-associated neurotoxicity

Print Friendly, PDF & Email


Attendees at 2018 ASCO Annual Meeting
©ASCO/Zach Boyden-Holmes 2018
A specific gene signature might be able to identify patients at risk of CD19 CAR T-cell associated neurotoxicity, according to results of an exploratory analysis presented at the 2018 ASCO Annual Meeting. The analysis, based on bone marrow samples from patients with relapsed/refractory B-cell acute lymphoblastic... [Read Article]
Print Friendly, PDF & Email

Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomab

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Prior exposure to blinatumomab does not appear to affect the successful manufacture of KTE-C19 or its efficacy in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The clinical benefit of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was preserved regardless of whether patients were exposed to... [Read Article]
Print Friendly, PDF & Email

bb2121 demonstrates durable responses, manageable toxicity in MM

Print Friendly, PDF & Email


Noopur S. Raje, MD
Photo by Andrew D. Bowser
bb2121, the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, induced deep and durable ongoing responses in heavily pretreated multiple myeloma (MM) patients, updated results of a phase 1 study show. At active doses (≥150 x 108 CAR+ T cells), the B-cell maturation antigen (BCMA)-targeted therapy produced... [Read Article]
Print Friendly, PDF & Email

Polatuzumab plus BR improves efficacy in DLBCL

Print Friendly, PDF & Email


Attendees at ASCO 2018
©ASCO/Zach Boyden-Holmes 2018
Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a phase 2 study. By contrast, there were no such improvements in a cohort of follicular lymphoma (FL)... [Read Article]
Print Friendly, PDF & Email

Two agents could take AML therapy in new directions

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Rodney White 2018
Two agents targeting novel pathways in myeloid malignancies—mivebresib and bencentinib—are showing promise in early studies, according to a speaker at the 2018 ASCO Annual Meeting. “Both BET and AXL inhibition appear to be new and exciting targets in myeloid malignancies,” said Alice S. Mims, MD, and both... [Read Article]
Print Friendly, PDF & Email

Single-agent acalabrutinib ‘impressive’ in patients with WM

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD, reported at the 2018 ASCO Annual Meeting. The BTK inhibitor was effective in both treatment-naïve and relapsed/refractory patients, with overall response rates for both groups in excess of 90%,... [Read Article]
Print Friendly, PDF & Email